Nothing Special   »   [go: up one dir, main page]

NO20025253D0 - Antistoff selektivt for en tumornekrosefaktor-relatert apoptose-induserende ligand reseptor og anvendelser derav - Google Patents

Antistoff selektivt for en tumornekrosefaktor-relatert apoptose-induserende ligand reseptor og anvendelser derav

Info

Publication number
NO20025253D0
NO20025253D0 NO20025253A NO20025253A NO20025253D0 NO 20025253 D0 NO20025253 D0 NO 20025253D0 NO 20025253 A NO20025253 A NO 20025253A NO 20025253 A NO20025253 A NO 20025253A NO 20025253 D0 NO20025253 D0 NO 20025253D0
Authority
NO
Norway
Prior art keywords
necrosis factor
tumor necrosis
ligand receptor
inducing ligand
related apoptosis
Prior art date
Application number
NO20025253A
Other languages
English (en)
Other versions
NO329843B1 (no
NO20025253L (no
Inventor
Tong Zhou
Kimihisa Ichikawa
Robert P Kimberly
William J Koopman
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of NO20025253D0 publication Critical patent/NO20025253D0/no
Publication of NO20025253L publication Critical patent/NO20025253L/no
Publication of NO329843B1 publication Critical patent/NO329843B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
NO20025253A 2000-05-02 2002-11-01 Renset antistoff samt anvendelse derav, in-vitro-metode, preparat og kommersielt sett NO329843B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20134400P 2000-05-02 2000-05-02
PCT/US2001/014151 WO2001083560A1 (en) 2000-05-02 2001-05-02 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Publications (3)

Publication Number Publication Date
NO20025253D0 true NO20025253D0 (no) 2002-11-01
NO20025253L NO20025253L (no) 2002-12-18
NO329843B1 NO329843B1 (no) 2011-01-10

Family

ID=22745456

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20025253A NO329843B1 (no) 2000-05-02 2002-11-01 Renset antistoff samt anvendelse derav, in-vitro-metode, preparat og kommersielt sett
NO20054145A NO338228B1 (no) 2000-05-02 2005-09-06 Fremgangsmåte for fremstilling av et antistoff

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20054145A NO338228B1 (no) 2000-05-02 2005-09-06 Fremgangsmåte for fremstilling av et antistoff

Country Status (28)

Country Link
US (6) US7244429B2 (no)
EP (4) EP2065400B1 (no)
JP (4) JP4156238B2 (no)
KR (2) KR100817967B1 (no)
CN (2) CN101585881B (no)
AT (1) ATE426615T1 (no)
AU (2) AU2001259366B2 (no)
BG (3) BG65929B1 (no)
BR (1) BR0110547A (no)
CA (1) CA2407965C (no)
CY (1) CY1109179T1 (no)
CZ (2) CZ304614B6 (no)
DE (1) DE60138097D1 (no)
DK (1) DK1287035T3 (no)
EE (1) EE05548B1 (no)
ES (1) ES2323448T3 (no)
HK (3) HK1050372A1 (no)
HU (2) HU230399B1 (no)
IL (1) IL152605A0 (no)
MX (1) MXPA02010823A (no)
NO (2) NO329843B1 (no)
NZ (1) NZ522881A (no)
PL (1) PL211733B1 (no)
PT (1) PT1287035E (no)
RU (1) RU2298013C2 (no)
TW (1) TWI318983B (no)
WO (1) WO2001083560A1 (no)
ZA (1) ZA200209230B (no)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
ES2281126T3 (es) 1997-03-17 2007-09-16 Human Genome Sciences, Inc. Receptor 5 que contiene un dominio de muerte.
CA2369371A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US7115717B2 (en) 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
NZ529359A (en) 2001-05-25 2007-04-27 Human Genome Sciences Inc Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
CA2463816C (en) 2001-10-19 2014-07-08 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
BRPI0213846B8 (pt) * 2001-11-01 2021-05-25 Uab Research Foundation composição que compreende um anticorpo que liga especificamente uma dr5 do receptor de trail e um ou mais agentes terapêuticos
KR20040070254A (ko) * 2001-12-20 2004-08-06 휎뚌 게놈 사읎얞시슈, 읞윔포레읎티드  수용첎에 멎역특읎적윌로 결합하는 항첎
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
DE10210427A1 (de) * 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
US7772372B2 (en) 2002-07-04 2010-08-10 Patrys Limited Neoplasm specific antibodies and uses thereof
AU2008201431B2 (en) * 2002-11-27 2011-11-24 Irm, Llc Methods and compositions for inducing Apoptosis in cancer cells
KR100915257B1 (ko) * 2002-11-27 2009-09-03 아읎알엠 엘엘씚 닚음큎론 항- 횚능제 항첎, ê·ž 항첎륌 발현하는 닚늬된 섞포, ê·ž 항첎륌 포핚하는 제앜 조성묌 및 ê·ž 항첎륌 사용하는 방법
DE10311248A1 (de) 2003-03-14 2004-09-30 MÌller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
DE10353175A1 (de) 2003-11-14 2005-06-16 MÌller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
AU2005227322A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
CN100427505C (zh) * 2004-08-19 2008-10-22 䞭囜医孊科孊院基础医孊研究所 抗人肿瘀坏死因子盞关凋亡诱富配䜓的受䜓dr5单克隆抗䜓ad5-10及其制法䞎甚途
CN102977205A (zh) * 2004-12-13 2013-03-20 赛北隆柳倧利亚(Vic)私人有限公叞 骚保技玠变匂蛋癜
AU2006210838B2 (en) 2005-02-02 2011-10-20 The Uab Research Foundation Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
JP5004154B2 (ja) * 2005-04-06 2012-08-22 䞀般財団法人化孊及血枅療法研究所 組換え抗ボツリヌス神経毒玠抗䜓
US8901281B2 (en) 2005-06-17 2014-12-02 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
CN101300273B (zh) * 2005-08-31 2013-05-22 安姆根有限公叞 Trail受䜓2倚肜和抗䜓
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
KR20090031359A (ko) 2006-05-16 2009-03-25 교와 핫ꌬ Ʞ늰 가부시킀가읎샀 닚백질의 고분비 생산 방법
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
KR100847010B1 (ko) * 2006-07-05 2008-07-17 아죌대학교산학협력닚 섞포사멞 수용첎 5 (5)에 특읎적윌로 결합하는 항첎 및읎륌 포핚하는 암 예방 또는 치료용 조성묌
KR100804126B1 (ko) 2007-02-09 2008-02-19 아죌대학교산학협력닚 종양 ꎎ사 읞자―ꎀ렚 섞포사멞―유도 늬간드의 수용첎에특읎적윌로 결합하는 1가의 읞간 닚음큎론 항첎 및 귞의항원결합 당펾
WO2008154439A1 (en) * 2007-06-08 2008-12-18 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
WO2009020094A1 (ja) * 2007-08-09 2009-02-12 Daiichi Sankyo Company, Limited 疎氎性分子で修食した抗䜓
US8409825B2 (en) 2007-10-31 2013-04-02 National Institute Of Advanced Industrial Science And Technology Method for high-level secretory production of protein
WO2010047509A2 (ko) * 2008-10-24 2010-04-29 아죌대학교 산학협력닚 친화도와 안정성읎 향상된 항 5 항첎, 및 읎륌 포핚하는 암 예방 또는 치료용 조성묌
JP2013505944A (ja) * 2009-09-24 2013-02-21 シアトル ゞェネティックス むンコヌポレむテッド リガンド薬物結合䜓
WO2011049350A2 (ko) * 2009-10-19 2011-04-28 한올바읎였파마죌식회사 변형된 읞간 종양 ꎎ사 읞자 수용첎-1 폎늬펩티드 또는 귞의 절펞 및 귞의 제조방법
WO2011057099A2 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
US9238069B2 (en) 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP3263583A1 (en) 2010-02-12 2018-01-03 Pharmascience Inc. Iap bir domain binding compounds
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
SG189456A1 (en) * 2010-10-29 2013-05-31 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
CN103561771B (zh) 2011-03-17 2019-01-04 䌯明翰倧孊 重新定向的免疫治疗
WO2012151317A1 (en) * 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
AU2013293062A1 (en) 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
RU2681730C2 (ru) * 2012-07-25 2019-03-12 СеллЎекс ТерапьютОкс ИМк. АМтОтела прПтОв kit О Ох прОЌеМеМОя
CN103074425B (zh) * 2012-12-29 2014-01-01 深圳垂第䞉人民医院 Cd263基因的甚途
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CN104710533A (zh) * 2013-12-12 2015-06-17 䞭囜科孊院深圳先进技术研究院 sDR5-Fc融合蛋癜及其甚途
SI3247728T1 (sl) 2015-01-20 2020-09-30 Igm Biosciences, Inc. Super-druÅŸina receptorjev, ki veÅŸejo molekule TNF (dejavnik tumorske nekroze), in njihova uporaba
RU2017129236A (ru) 2015-01-26 2019-03-07 МакрПЎжеМОкс, ИМк. МультОвалеМтМые ЌПлекулы, сПЎержащОе dr5-связывающОе ЎПЌеМы
CN105061604B (zh) * 2015-08-19 2018-03-16 河南倧孊 sDR5‑Fc融合蛋癜突变䜓及其应甚
EP3368076A4 (en) 2015-10-30 2019-08-28 Galaxy Biotech, LLC DEATH RECEPTOR 4 AND 5 BINDING HIGHLY EFFECTIVE ANTIBODIES
EP3383905A1 (en) 2015-12-01 2018-10-10 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
CN106924735A (zh) * 2015-12-29 2017-07-07 䞊海亀通倧孊医孊院附属瑞金医院 倚巎胺1类受䜓激劚剂圚制倇肿瘀治疗药物䞭的甚途
US10849912B2 (en) 2016-02-09 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
US10906987B2 (en) 2016-03-01 2021-02-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (PVR)
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재닚법읞 아산사회복지재닚 수용첎 시너지 활성을 읎용한 nk 섞포의 활성도 검사 방법 및 읎륌 읎용한 nk 섞포의 활성도가 ꎀ렚된 질환의 진닚 방법
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
KR101926834B1 (ko) 2017-03-21 2018-12-07 동아에슀티 죌식회사 항-dr5 항첎 및 귞의 용도
MX2019014407A (es) 2017-06-07 2020-02-05 Genmab Bv Anticuerpos terapeuticos basados en hexameros de inmunoglobulina g (igg) mutados.
KR101951025B1 (ko) 2017-08-17 2019-02-21 서욞대학교산학협력닚 섞포사멞 수용첎 저핎제륌 유횚성분윌로 포핚하는 cx3cl1 쌀몚칎읞 곌발현윌로 읞한 질환 예방 또는 치료용 조성묌
TW202428598A (zh) * 2017-09-22 2024-07-16 矎商免疫遺傳股仜有限公叞 䜿甚陜離子亀換局析法分離䞉茕鏈抗體
WO2019100194A1 (zh) * 2017-11-21 2019-05-31 深圳先进技术研究院 抗dr5的抗䜓及其制倇方法和应甚
WO2019100193A1 (zh) * 2017-11-21 2019-05-31 深圳先进技术研究院 抗dr5的抗䜓及其制倇方法和应甚
CN108251443A (zh) * 2018-01-23 2018-07-06 深圳垂人民医院 侀种tnfrsf10c重组莚粒、制倇方法及其应甚
US12018045B2 (en) 2018-03-06 2024-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer
CN117003874A (zh) 2018-03-20 2023-11-07 鞿运华宁杭州生物医药有限公叞 Gipr抗䜓及其䞎glp-1的融合蛋癜莚以及其药物组合物和应甚
JP2022514262A (ja) 2018-12-17 2022-02-10 レビトヌプ リミテッド 双子型免疫现胞゚ンゲヌゞャヌ
EP4277706A1 (en) 2021-01-15 2023-11-22 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
DE69837806T3 (de) 1997-01-28 2012-01-05 Human Genome Sciences, Inc. "death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US6313269B1 (en) 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
ES2281126T3 (es) 1997-03-17 2007-09-16 Human Genome Sciences, Inc. Receptor 5 que contiene un dominio de muerte.
AU734758B2 (en) 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies
CA2287085A1 (en) 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
JP2001511653A (ja) 1997-05-15 2001-08-14 ゞェネンテクむンコヌポレむテッド −レセプタヌ
WO1999002653A1 (en) 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
IL133920A0 (en) * 1997-07-15 2001-04-30 Immunex Corp Trail receptor
EP0934421A1 (en) 1997-08-06 1999-08-11 Laboratorio Medinfar-Produtos Farmaceuticos LDA. DNA INTEGRATION INTO "MYCOBACTERIUM spp." GENOME BY TRANS-COMPLEMENTATION USING A SITE-SPECIFIC INTEGRATION SYSTEM
EP1004001B1 (de) * 1997-08-13 2003-03-05 SorTech AG Sorptionsspeicher, anordnung und verfahren zur speicherung von wÀrme
JP2001514888A (ja) * 1997-08-15 2001-09-18 アむドゥン ファヌマシュヌティカルズ むンコヌポレむテッド レセプタヌ、これをコヌドする栞酞、およびその䜿甚方法
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
ATE360032T1 (de) 1997-09-12 2007-05-15 Biogen Idec Inc Cystein-reiche rezeptoren-train
US7105640B2 (en) * 1997-10-17 2006-09-12 Genentech, Inc. Anti-pro792 antibodies
US20040120947A1 (en) 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
ATE517125T1 (de) 1998-01-26 2011-08-15 Genentech Inc ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
IL145676A0 (en) 1999-04-12 2002-06-30 Genentech Inc Tumor necrosis factor homologs and nucleic acids encoding the same
CA2369371A1 (en) 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
WO2000067793A1 (en) 1999-05-06 2000-11-16 Human Genome Sciences, Inc. Death domain containing receptor 4
WO2000073349A1 (en) 1999-05-28 2000-12-07 Genentech, Inc. Dr4 antibodies and uses thereof
ATE330972T1 (de) 1999-06-09 2006-07-15 Genentech Inc Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
EP1616882A3 (en) 1999-09-15 2007-02-28 Genentech, Inc. Apo-2 receptor antibodies
ES2528794T3 (es) 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
WO2002079377A2 (en) 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US6965023B2 (en) 2000-11-17 2005-11-15 The Burnham Institute Death domain proteins
JP4509570B2 (ja) 2001-07-03 2010-07-21 ゞェネンテック むンコヌポレむテッド ヒト抗䜓及びその䜿甚法
BRPI0213846B8 (pt) 2001-11-01 2021-05-25 Uab Research Foundation composição que compreende um anticorpo que liga especificamente uma dr5 do receptor de trail e um ou mais agentes terapêuticos
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.

Also Published As

Publication number Publication date
EP2065400B1 (en) 2014-11-05
MXPA02010823A (es) 2004-05-05
BG107275A (bg) 2004-09-30
EE05548B1 (et) 2012-06-15
CN101585881B (zh) 2014-11-26
CY1109179T1 (el) 2014-07-02
CN100497388C (zh) 2009-06-10
US7790165B2 (en) 2010-09-07
US20140308288A1 (en) 2014-10-16
NO329843B1 (no) 2011-01-10
HK1126506A1 (zh) 2009-09-04
BG66153B1 (bg) 2011-08-31
US7244429B2 (en) 2007-07-17
TWI318983B (en) 2010-01-01
HK1162524A1 (zh) 2012-08-31
EP1287035B1 (en) 2009-03-25
NO20025253L (no) 2002-12-18
US20070298039A1 (en) 2007-12-27
HU0500800D0 (en) 2005-10-28
ZA200209230B (en) 2004-03-16
HK1050372A1 (en) 2003-06-20
US8067001B2 (en) 2011-11-29
CZ306996B6 (cs) 2017-11-01
NO338228B1 (no) 2016-08-08
EE200200621A (et) 2004-06-15
CA2407965C (en) 2014-10-14
NO20054145L (no) 2002-12-18
HU229417B1 (hu) 2013-12-30
DK1287035T3 (da) 2009-06-15
NZ522881A (en) 2005-05-27
CZ304614B6 (cs) 2014-08-06
KR20060092292A (ko) 2006-08-22
PL366195A1 (en) 2005-01-24
EP2065401B1 (en) 2016-08-10
EP2065401A3 (en) 2009-07-22
EP2368910B1 (en) 2016-02-10
US20110008324A1 (en) 2011-01-13
EP1287035A4 (en) 2004-09-29
WO2001083560A1 (en) 2001-11-08
HUP0400951A3 (en) 2012-09-28
CA2407965A1 (en) 2001-11-08
US20130243780A1 (en) 2013-09-19
EP2065401A2 (en) 2009-06-03
KR20030055177A (ko) 2003-07-02
EP2065400A2 (en) 2009-06-03
US8715668B2 (en) 2014-05-06
DE60138097D1 (de) 2009-05-07
ES2323448T3 (es) 2009-07-16
EP1287035A1 (en) 2003-03-05
RU2002132255A (ru) 2005-01-20
CZ2006291A3 (cs) 2017-11-01
AU2001259366B2 (en) 2005-09-08
JP4575975B2 (ja) 2010-11-04
PL211733B1 (pl) 2012-06-29
HUP0400951A2 (hu) 2004-07-28
US9700618B2 (en) 2017-07-11
BG65929B1 (bg) 2010-05-31
IL152605A0 (en) 2003-06-24
RU2298013C2 (ru) 2007-04-27
CZ20023917A3 (cs) 2003-05-14
JP4156238B2 (ja) 2008-09-24
JP2007091749A (ja) 2007-04-12
AU5936601A (en) 2001-11-12
CN1440424A (zh) 2003-09-03
KR100817967B1 (ko) 2008-03-31
ATE426615T1 (de) 2009-04-15
CN101585881A (zh) 2009-11-25
EP2368910A1 (en) 2011-09-28
US8329180B2 (en) 2012-12-11
US20030190687A1 (en) 2003-10-09
US20120076792A1 (en) 2012-03-29
EP2065400A3 (en) 2009-07-22
PT1287035E (pt) 2009-06-30
HU230399B1 (hu) 2016-04-28
JP2005232187A (ja) 2005-09-02
JP2009005707A (ja) 2009-01-15
JP2004502409A (ja) 2004-01-29
JP3892466B2 (ja) 2007-03-14
BR0110547A (pt) 2004-06-22
BG109275A (en) 2006-10-31

Similar Documents

Publication Publication Date Title
NO20025253D0 (no) Antistoff selektivt for en tumornekrosefaktor-relatert apoptose-induserende ligand reseptor og anvendelser derav
LTPA2005005I1 (lt) Antikūnai prieš VEGF
WO2004020404A3 (en) Modified transferin-antibody fusion proteins
EP2336190A3 (en) Anti-VEGF antibodies
AU2003270010A1 (en) Transferrin fusion protein libraries

Legal Events

Date Code Title Description
MK1K Patent expired